Malgorzata Anna Krawczyk1, Malgorzata Styczewska2, Ewa M Sokolewicz2, Michal Kunc3, Anna Gabrych4, Aleksandra Fatyga4, Ewa Izycka-Swieszewska5, Bernarda Kazanowska6, Elzbieta Adamkiewicz-Drozynska1, Ewa Bien1. 1. a Department of Paediatrics, Haematology and Oncology, Medical University of Gdansk , Gdansk , Poland. 2. b The English Division Paediatric Oncology Scientific Circle, Medical University of Gdansk , Gdansk , Poland. 3. c Department of Pathomorphology, Medical University of Gdansk , Gdansk , Poland. 4. d Department of Paediatrics, Haematology and Oncology, University Clinical Centre , Gdansk , Poland. 5. e Department of Pathology and Neuropathology, Medical University of Gdansk , Gdansk , Poland. 6. f Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Medical University of Wroclaw , Wroclaw , Poland.
Abstract
Objective: The study was to assess whether tumour expressions of hypoxia-inducible factor (HIF)-1α, glucose transporter (GLUT)-1, carbonic anhydrase (CA) IX and vascular endothelial growth factor (VEGF) predict response to neo-adjuvant chemotherapy (naCHT) in children with inoperable rhabdomyosarcoma (RMS). Methods: Immunohistochemical expressions of hypoxia markers were determined semi-quantitatively in tumour tissue microarray of 46 patients with embryonal RMS (RME) and 20 with alveolar (RMA), treated with CWS protocols (1992-2013). Results: In paediatric RME, response to naCHT was influenced significantly by tumour expression of CA IX and GLUT-1. Patients with RMA with low expressions of analysed markers responded well to naCHT, while all poor-responders expressed highly hypoxia markers. Only 5.88% of RMA and 11.11% of RME tumours did not express any of the proteins. In both RME and RMA subgroups, most poor-responders demonstrated simultaneous high expression of ≥3 markers, while most patients expressing ≤2 markers responded well to naCHT. In the whole cohort, co-expression of ≥3 markers, was the only independent factor predicting poor-response to chemotherapy (odds ratio 14.706; 95% CI 1.72-125.75; p = 0.014). Conclusions: Immunohistochemical expression pattern of four endogenous markers of hypoxia, in tumour tissue at diagnosis, emerges as a promising tool to predict response to naCHT in children with inoperable RMS.
Objective: The study was to assess whether tumour expressions of hypoxia-inducible factor (HIF)-1α, glucose transporter (GLUT)-1, carbonic anhydrase (CA) IX and vascular endothelial growth factor (VEGF) predict response to neo-adjuvant chemotherapy (naCHT) in children with inoperable rhabdomyosarcoma (RMS). Methods: Immunohistochemical expressions of hypoxia markers were determined semi-quantitatively in tumour tissue microarray of 46 patients with embryonal RMS (RME) and 20 with alveolar (RMA), treated with CWS protocols (1992-2013). Results: In paediatric RME, response to naCHT was influenced significantly by tumour expression of CA IX and GLUT-1. Patients with RMA with low expressions of analysed markers responded well to naCHT, while all poor-responders expressed highly hypoxia markers. Only 5.88% of RMA and 11.11% of RME tumours did not express any of the proteins. In both RME and RMA subgroups, most poor-responders demonstrated simultaneous high expression of ≥3 markers, while most patients expressing ≤2 markers responded well to naCHT. In the whole cohort, co-expression of ≥3 markers, was the only independent factor predicting poor-response to chemotherapy (odds ratio 14.706; 95% CI 1.72-125.75; p = 0.014). Conclusions: Immunohistochemical expression pattern of four endogenous markers of hypoxia, in tumour tissue at diagnosis, emerges as a promising tool to predict response to naCHT in children with inoperable RMS.
Entities:
Keywords:
CA IX; GLUT-1; HIF-1α; VEGF; children; response to neo-adjuvant chemotherapy; rhabdomyosarcoma
Authors: Mar Achalandabaso Boira; Marcello Di Martino; Carlos Gordillo; Magdalena Adrados; Elena Martín-Pérez Journal: BMC Cancer Date: 2020-09-23 Impact factor: 4.430
Authors: Carolina Bernauer; Y K Stella Man; Julia C Chisholm; Elise Y Lepicard; Simon P Robinson; Janet M Shipley Journal: Br J Cancer Date: 2020-10-27 Impact factor: 7.640